These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32257943)

  • 1. Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas.
    Yang B; Pan YB; Ma YB; Chu SH
    Front Oncol; 2020; 10():250. PubMed ID: 32257943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GNG5 is an unfavourable independent prognostic indicator of gliomas.
    Yang B; Han ZY; Wang WJ; Ma YB; Chu SH
    J Cell Mol Med; 2020 Nov; 24(21):12873-12878. PubMed ID: 33000557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
    Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
    PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.
    Wang P; Wu M; Tu Z; Tao C; Hu Q; Li K; Zhu X; Huang K
    Front Oncol; 2020; 10():1119. PubMed ID: 32974125
    [No Abstract]   [Full Text] [Related]  

  • 5. PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.
    Guadagno E; Vitiello M; Francesca P; Calì G; Caponnetto F; Cesselli D; Camorani S; Borrelli G; Califano M; Cappabianca P; Arra C; Crescenzi E; Cerchia L; De Caro MLDB; Fedele M
    Oncotarget; 2017 Aug; 8(35):59282-59300. PubMed ID: 28938636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma.
    Zhang W; Liu Z; Liu B; Jiang M; Yan S; Han X; Shen H; Na M; Wang Y; Ren Z; Liu B; Jiang Z; Gao Y; Lin Z
    Cancer Cell Int; 2021 Jun; 21(1):297. PubMed ID: 34098960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis.
    Zimu Z; Jia Z; Xian F; Rui M; Yuting R; Yuan W; Tianhong W; Mian M; Yinlong L; Enfang S
    Front Mol Biosci; 2021; 8():696072. PubMed ID: 34422904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
    Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
    Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of
    Ji X; Chen X; Lin G; Ma K; Yang J; Zhao X; Chen S; Yang J
    Front Cell Neurosci; 2024; 18():1440409. PubMed ID: 39360264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics and Prognosis Analysis of Epithelial-Mesenchymal Transition in Glioma.
    Tao C; Huang K; Shi J; Hu Q; Li K; Zhu X
    Front Oncol; 2020; 10():183. PubMed ID: 32154177
    [No Abstract]   [Full Text] [Related]  

  • 11. RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis.
    Shen F; Guo Q; Hu Q; Zeng A; Wu W; Yan W; You Y
    Oncol Lett; 2018 Apr; 15(4):4404-4410. PubMed ID: 29541209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas.
    Zhao M; Li X; Chen Y; Wang S
    Front Oncol; 2022; 12():854598. PubMed ID: 35372062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma.
    Liu R; Liu Z; Zhao Y; Cheng X; Liu B; Wang Y; Wang J; Lian X; Zhu Y; Gao Y
    Front Oncol; 2022; 12():726556. PubMed ID: 35928884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
    Guan X; Luo L; Begum G; Kohanbash G; Song Q; Rao A; Amankulor N; Sun B; Sun D; Jia W
    J Exp Clin Cancer Res; 2018 Oct; 37(1):255. PubMed ID: 30333031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.
    Yang Y; Wang J; Xu S; Shi F; Shan A
    Transl Neurosci; 2021 Jan; 12(1):67-75. PubMed ID: 33623713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
    Tsai CK; Huang LC; Tsai WC; Huang SM; Lee JT; Hueng DY
    Oncotarget; 2018 Mar; 9(21):15705-15720. PubMed ID: 29644003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.
    Ma K; Chen X; Liu W; Chen S; Yang C; Yang J
    Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
    Zeng F; Wang K; Huang R; Liu Y; Zhang Y; Hu H
    Oncol Lett; 2019 Jul; 18(1):386-394. PubMed ID: 31289510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.